Clinitech Laboratory Limited

As of March 31, 2026, Clinitech Laboratory Limited carries a market capitalization of 79.88M, placing it among publicly traded companies globally. Its enterprise value stands at 64.19M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Clinitech Laboratory Limited has 2.28M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Clinitech Laboratory Limited maintains a current ratio of 6.50, meaning it holds 6.5x the short-term assets needed to cover near-term liabilities.

As of the close on October 7, 2026, Clinitech Laboratory Limited's stock has declined approximately 27.11% over the past 52 weeks. The 50-day moving average sits at 38.73, while the 200-day moving average is 46.19.

As of March 31, 2026, Clinitech Laboratory Limited holds 21.12M in cash and equivalents against 5.38M in total debt, resulting in a net debt position of -15.75M. Total book value stands at 92.48M, with working capital of 62.40M providing operational flexibility.